Stereotaxis: An Improving Product, Priced for the Risk That It Stalls

Here is a company whose own filings describe a product finally working — a proprietary heart-ablation catheter that grew roughly 450% year over year in the latest quarter — and yet the stock trades near $1.39, about 29% below its 200-day average. That gap has nothing to do with the story being puffed up. In fact, the opposite reading is likelier: the market is not pricing in success at all. It is pricing in the risk that Stereotaxis runs out of time — or cash — before its new revenue engine scales.

Stereotaxis is not the kind of name my screen normally surfaces. It is a roughly $140 million micro-cap that loses money every quarter, so most of the standard factor grades come back ungradeable. What you can score is one discrete trajectory, and it is moving in the right direction. The question is whether that improving report card outruns the clock.

Why the top line is shrinking even as the product works

Stereotaxis sells robotic magnetic-navigation systems — the Genesis magnetic robot that helps electrophysiologists guide catheters through the heart — but the real economics live in the consumables. Each procedure uses a catheter, and the company has spent years moving from catheters supplied by Johnson & Johnson onto its own proprietary MAGiC catheter. The payoff is per-procedure pricing several times higher than the legacy arrangement, quoted in the range of $5,000 to $8,000 per case in the U.S.

That shift is why the reported numbers look so contradictory. In the second quarter, total revenue was $7.7 million, down from $8.8 million a year earlier — a 13% decline. The fall is partly self-inflicted: the company is deliberately winding down the J&J catheter business while the new line is still constrained by a contract manufacturer's output. Systems revenue, which is lumpy and tied to robot installs, also halved from $3.0 million to $1.5 million. Strip those out and the engine is actually turning: recurring disposable-and-service revenue rose to $6.2 million from $5.8 million, and the MAGiC catheter line alone generated $1 million, up 270% sequentially off a tiny base.

So the improving report card is buried under a shrinking headline. The only recorded grade that matters here is the trajectory of that recurring line — and its bottleneck is not demand but supply. Management says order volume already exceeds what contract manufacturer Osypka can ship, and it is targeting the capacity to make 500 catheters a month by year-end. If that output argument holds, the recurring curve steepens through the second half.

The swing factor is the cash clock, not the product

Now the safety check, because in a loss-making micro-cap the balance sheet is the rating. As of June 30 Stereotaxis held $10.5 million in cash and carried no debt. It also burned roughly $3.7 million of free cash flow in the quarter, about the same as the year-ago period. Do the math: at that pace the cushion is roughly two, maybe three, quarters of runway.

Management is explicit that this is the plan — it targets cash-flow profitability in the first half of 2027 and guided full-year revenue above $40 million, with both the third and fourth quarters each landing above $10 million. Those are ambitious step-ups from a $7.7 million quarter. They depend on the 500-catheter capacity coming online and flowing through at north of mid-60% recurring gross margins toward a mid-70% target. Every one of those moving parts is an execution assumption, and the company's own guidance leans on them for survival, not just for growth.

That is the honest tension the price is expressing. Analysts still rate the stock a consensus Strong Buy with an average target near $3.00 — about double the current price — but those targets were themselves cut repeatedly this year, from as high as $5.00, as the transition stretched out. At $1.39, with weak momentum (below both its 50-day and 200-day averages and a neutral RSI), there is no technical confirmation backing the story. This is not a breakout; it is a turnaround held together by one variable.

What the factor stack actually says to do

In portfolio terms, this belongs in the aggressive satellite sleeve, not the core. It is a bet on a single, discrete milestone — can the catheter ramp outrun the cash burn and reach breakeven by the guided window — and the structure that fits an uncertain, binary outcome is position size, not conviction. A name this small, this loss-making, and this supply-bound can halve on one missed quarter, so the discipline is in how much you allocate and in watching the specific trigger: quarterly recurring-revenue step-ups and the cash balance quarter over quarter. If recurring revenue keeps compounding and cash is still there in early 2027, the improving report card becomes an actual growth story. If the burn outpaces the ramp, the clock is the answer, and the sub-$1 handling of it becomes a much harder process to own.

The useful correction to the "priced-in success" framing is that the market has done the opposite. It has walked the price down, slashed targets, and left the stock below its averages precisely because it doubts the timing. The product thesis is real and improving. Whether it wins is a supply-and-cash race, and that is the only number worth watching.